BioCentury | May 10, 2019
Emerging Company Profile

HopeMed: Targeting PRLR for chronic diseases

HopeMed spun out of Peking University last month with a mAb against the prolactin receptor from Bayer that could provide a safe alternative to competing therapies for endometriosis and alopecia. Hope Medicine Inc. has exclusive...
BC Week In Review | Apr 12, 2019
Company News

Xoma gains milestone and royalty rights to Aronora's hematology assets

Xoma acquired royalty payments and a portion of potential milestones associated with five hematology assets from Aronora. Xoma Corp. (NASDAQ:XOMA) will pay $6 million up front to receive 10% of milestones for each asset plus...
BC Innovations | Dec 14, 2018
Product R&D

Gene therapy’s make or buy choice

Whether or not to bring manufacturing in-house for gene therapy companies is becoming a critical choice, as contract manufacturers struggle to keep up with demand. The trade-off for the upfront investment risk is control over...
BC Extra | Jan 9, 2018
Company News

Management tracks: OncoMed, Neurocrine

Cancer company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Chairman, President and CEO Paul Hastings has resigned. The company is seeking a replacement. Perry Karsen will serve as chairman. Hastings began a medical leave of absence on...
BC Week In Review | Sep 1, 2017
Company News

Xoma, Novartis partner for IL-1 beta mAbs and related IP

Xoma Corp. (NASDAQ:XOMA) granted Novartis AG (NYSE:NVS; SIX:NOVN) exclusive, worldwide rights to commercialize IL-1 beta mAb candidate gevokizumab ( XOMA 052 ). The company also granted Novartis a non-exclusive license to IP covering IL-1 beta -targeting...
BC Extra | Aug 28, 2017
Clinical News

Canakinumab reduces lung cancer mortality, headed for Phase III

Novartis AG (NYSE:NVS; SIX:NOVN) said canakinumab (ACZ885) significantly reduced lung cancer incidence and associated mortality vs. placebo in the Phase III CANTOS cardiovascular outcomes trial in patients with a prior heart attack and inflammatory atherosclerosis....
BC Extra | Aug 25, 2017
Company News

Xoma gains on Novartis IL-1 beta mAb deals

Xoma Corp. (NASDAQ:XOMA) jumped $2.17 (24%) to $11.10 on Friday after granting Novartis AG (NYSE:NVS; SIX:NOVN) worldwide rights to commercialize IL-1 beta mAb candidate gevokizumab (XOMA 052). The company also granted Novartis a non-exclusive license...
BC Week In Review | Mar 17, 2017
Clinical News

XOMA 358: Ph II data

Data from 13 patients ages 42-68 with hypoglycemia post-bariatric surgery in an open-label, U.S. Phase II trial showed that single doses of 3, 6 and 9 mg/kg IV XOMA 358 were generally well tolerated. XOMA...
BC Week In Review | Mar 17, 2017
Clinical News

XOMA 358: Additional Ph II data

Additional data from an open-label, international Phase II trial in 14 patients ages 12-37 with hypoglycemia associated with congenital hyperinsulinism showed that single doses of IV XOMA 358 reduced the duration of hypoglycemia by 25-70%...
BC Week In Review | Feb 16, 2017
Financial News

Xoma completes direct public offering

Antibody developer Xoma Corp. (NASDAQ:XOMA) raised $25 million through the sale of 1.2 million shares at $4.03 and 5,003 convertible preferred shares at $4,030 in a registered direct offering to existing investor Biotechnology Value Fund...
Items per page:
1 - 10 of 752
BioCentury | May 10, 2019
Emerging Company Profile

HopeMed: Targeting PRLR for chronic diseases

HopeMed spun out of Peking University last month with a mAb against the prolactin receptor from Bayer that could provide a safe alternative to competing therapies for endometriosis and alopecia. Hope Medicine Inc. has exclusive...
BC Week In Review | Apr 12, 2019
Company News

Xoma gains milestone and royalty rights to Aronora's hematology assets

Xoma acquired royalty payments and a portion of potential milestones associated with five hematology assets from Aronora. Xoma Corp. (NASDAQ:XOMA) will pay $6 million up front to receive 10% of milestones for each asset plus...
BC Innovations | Dec 14, 2018
Product R&D

Gene therapy’s make or buy choice

Whether or not to bring manufacturing in-house for gene therapy companies is becoming a critical choice, as contract manufacturers struggle to keep up with demand. The trade-off for the upfront investment risk is control over...
BC Extra | Jan 9, 2018
Company News

Management tracks: OncoMed, Neurocrine

Cancer company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Chairman, President and CEO Paul Hastings has resigned. The company is seeking a replacement. Perry Karsen will serve as chairman. Hastings began a medical leave of absence on...
BC Week In Review | Sep 1, 2017
Company News

Xoma, Novartis partner for IL-1 beta mAbs and related IP

Xoma Corp. (NASDAQ:XOMA) granted Novartis AG (NYSE:NVS; SIX:NOVN) exclusive, worldwide rights to commercialize IL-1 beta mAb candidate gevokizumab ( XOMA 052 ). The company also granted Novartis a non-exclusive license to IP covering IL-1 beta -targeting...
BC Extra | Aug 28, 2017
Clinical News

Canakinumab reduces lung cancer mortality, headed for Phase III

Novartis AG (NYSE:NVS; SIX:NOVN) said canakinumab (ACZ885) significantly reduced lung cancer incidence and associated mortality vs. placebo in the Phase III CANTOS cardiovascular outcomes trial in patients with a prior heart attack and inflammatory atherosclerosis....
BC Extra | Aug 25, 2017
Company News

Xoma gains on Novartis IL-1 beta mAb deals

Xoma Corp. (NASDAQ:XOMA) jumped $2.17 (24%) to $11.10 on Friday after granting Novartis AG (NYSE:NVS; SIX:NOVN) worldwide rights to commercialize IL-1 beta mAb candidate gevokizumab (XOMA 052). The company also granted Novartis a non-exclusive license...
BC Week In Review | Mar 17, 2017
Clinical News

XOMA 358: Ph II data

Data from 13 patients ages 42-68 with hypoglycemia post-bariatric surgery in an open-label, U.S. Phase II trial showed that single doses of 3, 6 and 9 mg/kg IV XOMA 358 were generally well tolerated. XOMA...
BC Week In Review | Mar 17, 2017
Clinical News

XOMA 358: Additional Ph II data

Additional data from an open-label, international Phase II trial in 14 patients ages 12-37 with hypoglycemia associated with congenital hyperinsulinism showed that single doses of IV XOMA 358 reduced the duration of hypoglycemia by 25-70%...
BC Week In Review | Feb 16, 2017
Financial News

Xoma completes direct public offering

Antibody developer Xoma Corp. (NASDAQ:XOMA) raised $25 million through the sale of 1.2 million shares at $4.03 and 5,003 convertible preferred shares at $4,030 in a registered direct offering to existing investor Biotechnology Value Fund...
Items per page:
1 - 10 of 752